Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Jingbo Hu, Chunlin Yang, Hongbo Wang, Jing Li, Xueying Tan, Jinhui Wang, Bin Zhang & Yufen Zhao. (2019) An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 20:14, pages 1679-1687.
Read now
Read now
Dieter Ayers, Steve Kanters, Rachel Goldgrub, Monica Hughes, Ryo Kato & Nana Kragh. (2017) Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients. Current Medical Research and Opinion 33:9, pages 1653-1661.
Read now
Read now
Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now
Read now
Keith C. Ferdinand & Samar A. Nasser. (2015) Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. Current Medical Research and Opinion 31:5, pages 913-923.
Read now
Read now
Yutaka Seino & Daisuke Yabe. (2014) Alogliptin for the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 9:6, pages 547-559.
Read now
Read now
Kohei Kaku, Mikiko Mori, Tatsuhiro Kanoo, Masafumi Katou & Yutaka Seino. (2014) Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opinion on Pharmacotherapy 15:15, pages 2121-2130.
Read now
Read now
Kohei Kaku. (2014) Efficacy of voglibose in type 2 diabetes. Expert Opinion on Pharmacotherapy 15:8, pages 1181-1190.
Read now
Read now
Yutaka Seino & Daisuke Yabe. (2014)
Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 15:6, pages 851-863.
Read now
Read now
Annalisa Capuano, Liberata Sportiello, Maria Ida Maiorino, Francesco Rossi, Dario Giugliano & Katherine Esposito. (2013) Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. Drug Design, Development and Therapy 7, pages 989-1001.
Read now
Read now
Masanobu Aramaki. (2013) Alogliptin, but not voglibose, ameliorates dyslipidemia and LDL particle size in patients with impaired glucose tolerance or Type 2 diabetes. Clinical Lipidology 8:5, pages 533-540.
Read now
Read now
Kiyomi Masuda, Kazutaka Aoki, Kazunari Kamiko, Masahiro Takihata, Yuzuru Ito, Mieko Nagakura, Satsuki Kawasaki, Noriko Akema, Maki Hasegawa, Shigeru Nakajima, Kazuaki Shinoda, Shyoken Toumura, Seishi Tsunoda, Hitoshi Enomoto, Hidefumi Shimotomai & Yasuo Terauchi. (2013) Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors. Expert Opinion on Pharmacotherapy 14:9, pages 1111-1118.
Read now
Read now
Yuki Fujii, Masanori Abe, Terumi Higuchi, Mari Mizuno, Hiroko Suzuki, Shiro Matsumoto, Midori Ito, Noriaki Maruyama, Kazuyoshi Okada & Masayoshi Soma. (2013) The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opinion on Pharmacotherapy 14:3, pages 259-267.
Read now
Read now
Articles from other publishers (36)
Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak & Linong Ji. (2022) Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis. Frontiers in Endocrinology 13.
Crossref
Crossref
Mototsugu Tanaka, Mayumi Idei, Hiroshi Sakaguchi, Ryosuke Kato, Daisuke Sato, Kenji Sawanobori, Shuichi Kawarasaki, Toshiyuki Hata, Asako Yoshizaki, Miki Nakamura & Mutsuhiro Ikuma. (2021) Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan. British Journal of Clinical Pharmacology 87:8, pages 3279-3291.
Crossref
Crossref
Wenjia Yang, Xiaoling Cai, Simin Zhang, Xueyao Han & Linong Ji. (2020) Dipeptidyl peptidase‐4 inhibitor treatment and the risk of bullous pemphigoid and skin‐related adverse events: A systematic review and meta‐analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews 37:3.
Crossref
Crossref
Chu Lin, Xiaoling Cai, Wenjia Yang, Fang Lv, Lin Nie & Linong Ji. (2020) Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC Medicine 18:1.
Crossref
Crossref
Sanjay Kalra, A Panneer Selvam, Amish V Shah, Kudugunti Neelaveni, Navneet Agrawal, Sambit Das, Vinay K Dhandhania, Subodh Jain, Pankaj Kumar Jha & Neha Raval. (2020) Prospective Multicenter Observational Study of Voglibose in Type 2 Diabetes—VICTORY. US Endocrinology 16:1, pages 31.
Crossref
Crossref
Kohei Kaku, Koichi Kisanuki, Mari Shibata & Takashi Oohira. (2019) Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus. Drug Safety 42:11, pages 1311-1327.
Crossref
Crossref
N. A. PetuninaA. L. Terekhova. (2019) Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin. Medical Council:21, pages 138-145.
Crossref
Crossref
Hae Kyung Yang, Seung-Hwan LeeJuyoung ShinYoon-Hee ChoiYu-Bae AhnByung-Wan LeeEun Jung RheeKyung Wan MinKun-Ho Yoon. (2019) Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Diabetes & Metabolism Journal 43:3, pages 287.
Crossref
Crossref
Se Hee Min, Jeong-Hwa Yoon, Seokyung Hahn & Young Min Cho. (2018) Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis. Journal of Diabetes Investigation 9:4, pages 893-902.
Crossref
Crossref
Sofie Hædersdal, Asger Lund, Filip K. Knop & Tina Vilsbøll. (2018) The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. Mayo Clinic Proceedings 93:2, pages 217-239.
Crossref
Crossref
Yuli Cai, Tianshu Zeng, Zhongyuan Wen & Lulu Chen. (2017) Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-Analysis. Diabetes Therapy 9:1, pages 177-191.
Crossref
Crossref
N. A. Petunina, E. V. Goncharova & S. A. Potapova. (2017) CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN. Medical Council:3, pages 32-37.
Crossref
Crossref
Xiafei Lyu, Xiaolin Zhu, Bin Zhao, Liang Du, Dawei Chen, Chun Wang, Guanjian Liu & Xingwu Ran. (2017) Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Scientific Reports 7:1.
Crossref
Crossref
Kayo Fujita, Masayuki Kaneko & Mamoru Narukawa. (2016) Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions. Clinical Drug Investigation 37:3, pages 219-232.
Crossref
Crossref
José E. Rodríguez & Kendall M. Campbell. (2017) Racial and Ethnic Disparities in Prevalence and Care of Patients With Type 2 Diabetes. Clinical Diabetes 35:1, pages 66-70.
Crossref
Crossref
Xiaolong Chen, Yuele Lu, Yongxian Fan & Yinchu Shen. 2017. Validamycin and its Derivatives. Validamycin and its Derivatives
237
278
.
Lingyu He, Shu Liu, Chun Shan, Yingmei Tu, Zhengqing Li & Xiaohua Douglas Zhang. (2016) Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis. BMC Pharmacology and Toxicology 17:1.
Crossref
Crossref
Helene Bihan, Winda L. Ng, Dianna J. Magliano & Jonathan E. Shaw. (2016) Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review. Diabetes Research and Clinical Practice 121, pages 27-34.
Crossref
Crossref
Wenjia Yang, Xiaoling Cai, Xueyao Han & Linong Ji. (2016) DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews 32:4, pages 391-404.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:12, pages 1225-1238.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
Crossref
M. E. Rotz, V. S. Ganetsky, S. Sen & T. F. Thomas. (2015) Implications of incretin-based therapies on cardiovascular disease. International Journal of Clinical Practice 69:5, pages 531-549.
Crossref
Crossref
Xiaoling Cai, Xueyao Han, Yingying Luo & Linong Ji. (2014)
Efficacy of dipeptidyl‐peptidase‐4 inhibitors and impact on
β
‐cell function in
A
sian and
C
aucasian type 2 diabetes mellitus patients: A meta‐analysis在亚洲人和白种人的2型糖尿病患者中DPP‐4抑制剂的疗效及对
β
细胞功能的影响：一项meta分析
. Journal of Diabetes 7:3, pages 347-359.
Crossref
Crossref
Gillian M. Keating. (2015) Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75:7, pages 777-796.
Crossref
Crossref
Hiromi HamamotoKoji NakanishiMitsuhiko Noda. (2015) Analyzing the Factors Contributing to Withdrawal from Insulin Therapy following Additional Administration of Alogliptin: Retrospective Study after Removing Glucotoxicity with Insulin. Japanese Clinical Medicine 6, pages JCM.S27202.
Crossref
Crossref
George Grunberger. (2014) Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. European Journal of Clinical Pharmacology 70:11, pages 1277-1289.
Crossref
Crossref
Dae Ho Lee. (2014) Dipeptidyl Peptidase-4 Inhibitor. Korean Journal of Medicine 87:1, pages 1.
Crossref
Crossref
Kohzo Takebayashi, Shintaro Sakurai, Tatsuhiko Suzuki, Kenichiro Hori, Tomoko Terasawa, Rika Naruse, Kenji Hara, Mariko Suetsugu, Takafumi Tsuchiya, Hiromi Aoki, Takashi Hamasaki, Hiroshi Shuutou & Toshihiko Inukai. (2014) Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes. Endocrine Journal 61:10, pages 1031-1039.
Crossref
Crossref
Mitsuyoshi Takahara, Toshihiko Shiraiwa, Naoto Katakami, Hideaki Kaneto, Taka-aki Matsuoka & Iichiro Shimomura. (2014) Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin. Endocrine Journal 61:5, pages 447-456.
Crossref
Crossref
Kazutaka Aoki, Hiroshi Kamiyama, Kiyomi Masuda, Kazunari Kamiko, Yoshihiko Noguchi, Kazuki Tajima & Yasuo Terauchi. (2014) Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels. Endocrine Journal 61:3, pages 249-256.
Crossref
Crossref
Asres Berhan & Yifru Berhan. (2013) Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocrine Disorders 13:1.
Crossref
Crossref
Koji Sakata, Manabu Hayakawa, Yuichiro Yano, Noboru Tamaki, Naoto Yokota, Takuma Eto, Reiko Watanabe, Naoteru Hirayama, Takeshi Matsuo, Kazuo Kuroki, Seiji Sagara, Osamu Mishima, Masahiro Koga, Naoto Nagata, Yuri Nishino, Kazuo Kitamura, Kazuomi Kario, Masayoshi Takeuchi & Sho‐ichi Yamagishi. (2013) Efficacy of alogliptin, a dipeptidyl peptidase‐4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) – receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes/Metabolism Research and Reviews 29:8, pages 624-630.
Crossref
Crossref
Y. G. Kim, S. Hahn, T. J. Oh, S. H. Kwak, K. S. Park & Y. M. Cho. (2013) Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 56:4, pages 696-708.
Crossref
Crossref
Makoto Ayaori, Naotsugu Iwakami, Harumi Uto‐Kondo, Hiroki Sato, Makoto Sasaki, Tomohiro Komatsu, Maki Iizuka, Shunichi Takiguchi, Emi Yakushiji, Kazuhiro Nakaya, Makiko Yogo, Masatsune Ogura, Bonpei Takase, Takehiko Murakami & Katsunori Ikewaki. (2013) Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients. Journal of the American Heart Association 2:1.
Crossref
Crossref
Yoshiki Kusunoki, Tomoyuki Katsuno, Makiko Myojin, Kana Miyakoshi, Takashi Ikawa, Toshihiro Matsuo, Fumihiro Ochi, Masaru Tokuda, Kazuki Murai, Masayuki Miuchi, Tomoya Hamaguchi, Jun-ichiro Miyagawa & Mitsuyoshi Namba. (2013) Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocrine Journal 60:4, pages 431-439.
Crossref
Crossref
Yutaka Seino, Shinzo Hiroi, Masashi Hirayama & Kohei Kaku. (2012) Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study. Journal of Diabetes Investigation 3:6, pages 517-525.
Crossref
Crossref